US clinical stage biotech Provention Bio (Nasdaq: PRVB) saw its shares leap 12.4% after it announced a deal with its much larger peer Amgen (Nasdaq; AMGN) for the co-development of AMG 714, now re-designated by Provention as PRV-015.
AMG 714 is a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (NRCD). Development efforts at Provention will be led by researchers with previous experience developing AMG 714.
Amgen will invest $20 million in Provention during its next financing as part of the agreement, which will see Provention conduct and fund a Phase IIb trial and lead the next phase of development and regulatory activities for the program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze